pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 20·1 min read
save

Weekly roundup highlights LGBTQ+ leadership in biopharma and reports of a Novo Nordisk hack

Jun 20, 2026·read at Endpoints ↗Neutral

The latest Endpoints Weekly newsletter was published on June 20, 2026, coinciding with the summer solstice in the northern hemisphere.

The issue spotlights the growing visibility of LGBTQ+ leaders within the biopharma sector, highlighting their contributions and the industry's evolving inclusivity.

It also raises concerns about a potential cyber intrusion at Novo Nordisk, prompting readers to watch for further developments.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more”

read at Endpoints ↗
84 words · retrieved Jul 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO2Novo Nordisk Inc2

related stories

  • May 7Seaport’s IPO adventure, obesity pill battles, and Makary’s troublesSTAT
  • May 7STAT+: FDA revisits a rare cancer treatment it rejected a few months agoSTAT
  • May 7STAT+: FDA to reconsider treatment for rare cancer after its surprise rejectionSTAT
  • May 7STAT+: Next-gen Duchenne drug from Entrada disappointsSTAT
  • May 7STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1BSTAT